REMEDI GROUP

WHO WE ARE

Born in Europe, made in Italy, rises from the union of Rigenera Human Brain Wave and Regenera Activa, two expert and reference companies in the world of regenerative medicine, Remedi proudly asserts its position as the first company to introduce authentic tissue regeneration through micrograft technology.

We're a pioneering European biotech company with bases in Torino and Barcelona, known for our leadership in Autologous and Tissue Specific Micrograft solutions using our exclusive patented Rigenera® Technology.

Operating in more than 70 countries, thousands of clinics and doctors trust us for cutting-edge regenerative medical solutions.

Our mission is to develop and promote innovative regenerative technology easily accessible by patients and healthcare professionals. The company invests in extensive research & development of innovative medical technology.

STATE OF THE ART FACILITIES

We proudly spotlight our new facilities located in the Polo Tecnologico Piemontese in Turin. Here, not only do we manufacture our cutting-edge Rigenera® medical devices, but we also house a dedicated scientific research center focused on innovative advances in the field of regenerative medicine.
Through rigorous research initiatives and advanced technological development, we are committed to keep making progress and improving patients’ lives worldwide.

Timeline

With over two decades of dedicated scientific research, we proudly affirm our commitment to innovation and showcase our extensive expertise within regenerative medicine technology.

2006

Dr. Graziano and Dr. D’Aquino were involved in the field of scientific research in Naples. They realized that from a simple filtering work it is possible to improve biological performance of the tissue and, therefore, its ability to intrinsic healing

2012

Human Brain Wave (HBW) is founded in Italy for the fabrication and distribution of Rigenera® Technology.

2013

First prototype of Rigenera® Technology is tested in the Italian market in Odontology and Wound Healing field.

2014

Rigenera® Technology is patented and the first Autologous Micrografting Technology® protocol with use of Rigenera® are developed.

2016

Regenera Activa begins its expansion in the European, Asian, and South American markets. The protocol on Hair Restoration is implemented.

2018

Regenera Activa starts contracts with Middle East, Asia & Australia, while expands its Traumatology line with new distributors in Spain & South America.

2022

Opening of Polo Tecnologico Piemontese (PTP) and launch of Rigenera Hong Kong office.

2024

Remedi's official announcement during IMCAS congress in Paris.
Also, New studies conducted in collaboration with the University of Ferrara and the University of Barcelona demonstrate the presence of human smart exosomes in the Regenera Activa protocol micrograft.

OUR VALUES

HIGH QUALITY

We assure the highest standards of quality for our products and treatments, endorsed by both European and international certifications, as well as our patented Rigenera® technology.

SCIENTIFIC EXCELLENCE

We are the pioneers in Autologous Micrografting, and research applied to regenerative medicine, elevating the outcomes obtained with our technology and treatments to the next level.

MAXIMUM SAFETY

We are committed with the safety and well-being of our patients above all else. We stick rigorously to safety protocols and standards in the development and manufacturing of our products. From R&D to clinical practice, we ensure the highest level of safety for patients and healthcare professionals.

PATIENT-CENTRIC APPROACH

We believe in improving patient lives. Our treatments are designed to be minimally invasive and, as they are homologous, without any risk of rejection or side effects. The patient can continue with his daily routine without experiencing any discomfort.